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Abstract
Sphingosylphosphorylcholine (SPC) induces differ-
entiation of human adipose tissue-derived mesen-
chymal stem cells (hASCs) into smooth muscle-like 
cells expressing α-smooth muscle actin (α-SMA) via 
transforming growth factor-β1/Smad2- and RhoA/Rho 
kinase-dependent mechanisms. 3-Hydroxy-3-methyl-
glutaryl-coenzyme  A  reductase  inhibitors  (statins) 
have been known to have beneficial effects in the treat-
ment of cardiovascular diseases. In the present study, 
we examined the effects of simvastatin on the SPC-in-
duced α-SMA expression and Smad2 phosphorylation 
in  hASCs.  Simvastatin  inhibited  the  SPC-induced 
α-SMA expression and sustained phosphorylation of 
Smad2 in hASCs. SPC treatment caused RhoA activa-
tion  via  a  simvastatin-sensitive  mechanism.  The 
SPC-induced α-SMA expression and Smad2 phos-
phorylation were abrogated by pretreatment of the 
cells with the Rho kinase inhibitor Y27632 or over-
expression  of  a  dominant  negative  RhoA  mutant. 
Furthermore, SPC induced secretion of TGF-β1 and 
pretreatment with either Y27632 or simvastatin in-
hibited the SPC-induced TGF-β1 secretion. These re-
sults suggest that simvastatin inhibits SPC-induced 
differentiation of hASCs into smooth muscle cells by 
attenuating the RhoA/Rho kinase-dependent activa-
tion of autocrine TGF-β1/Smad2 signaling pathway.
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Introduction
Smooth muscle cells (SMCs) play an important 
role in angiogenesis, vessel maintenance, and reg-
ulation of blood pressure. SMCs exhibit a con-
tractile phenotype characterized by high expression 
of specific contractile proteins, including α-SMA, 
calponin-1, SM22α, smoothelin, h-caldesmon, and 
smooth muscle myosin heavy chain (Shanahan et 
al., 1993; Owens et al., 2004). The phenotypic ex-
pression of SMCs is implicated in vascular devel-
opment as well as in a variety of cardiovascular 
diseases, including hypertension and athero-
sclerosis (Liu et al., 2004; Owens et al., 2004). 
    Mesenchymal stem cells (MSCs) have a self-re-
newal capacity, long-term viability, and potential to 
differentiate into cells of diverse lineages, such as 
adipogenic, osteogenic, chondrogenic, and myo-
genic lineages (Pittenger and Martin, 2004; Caplan, 
2007; Chamberlain et al., 2007; Prockop et al., 2010). 
Bone marrow-derived MSCs have been shown to 
differentiate to smooth muscle cells (SMCs) in re-
sponse to transforming growth factor-β (TGF-β) 160    Exp. Mol. Med. Vol. 44(2), 159-166, 2012
Figure 1. Effect of simvastatin on SPC-induced expression of smooth 
muscle markers in hASCs. (A) hASCs were treated with serum-free me-
dium containing 2 μM SPC or vehicles (0.1% DMSO, w/o) in the pres-
ence of indicated concentrations of simvastatin for 4 days. Expression 
levels of α-SMA, calponin, and GAPDH were determined by Western 
blotting. (B) Inhibitory effects of simvastatin on SPC-induced α-SMA ex-
pression in hASCs were further determined by immunostaining with an-
ti-α-SMA antibody. Scale bar = 50 μm. Representative data from three 
independent experiments are shown.
(Kinner et al., 2002; Wang et al., 2004), mechan-
ical stress (Kobayashi et al., 2004), and direct con-
tact with vascular endothelial cells in vitro (Ball et 
al., 2004). Moreover, injected bone marrow-derived 
MSCs have been reported to have differentiated in-
to SMCs and to have contributed to the remodeling 
of vasculature in vivo (Davani et al., 2003; Gojo et 
al., 2003; Yoon et al., 2005). In a previous study, we 
showed that sphingosylphosphorylcholine (SPC) 
increased the expression levels of α-SMA and oth-
er smooth muscle-specific proteins in human adi-
pose tissue-derived mesenchymal stem cells 
(hASCs) via an autocrine TGF-β/Smad2-dependent 
mechanism (Jeon et al., 2006). In addition, we 
have previously reported that SPC stimulated the 
small GTPase RhoA and that the RhoA-Rho kin-
ase pathway played a key role in SPC-induced dif-
ferentiation of hASCs to SMCs. RhoA-Rho kinase 
pathway plays a key role in SMC differentiation by 
regulating the integrity of the actin cytoskeleton 
and MRTF-dependent gene transcription (Cen et 
al., 2004; Miano et al., 2007). Therefore, SPC-in-
duced SMC differentiation of MSCs would be an ideal 
model for the study of vascular diseases-associated 
SMC differentiation. 
    3-Hydroxy-3-methylglutaryl coenzyme A (HMG- 
CoA) reductase inhibitors (statins) reportedly exert 
beneficial effects in patients with cardiovascular 
diseases via pleiotropic functions, including reduc-
tion of plaque inflammation and platelet ag-
gregation, enhanced plaque stability and endothe-
lial function, and inhibition of SMC proliferation and 
increased apoptosis (Calabro and Yeh, 2005; Liao, 
2005). Accumulating evidence suggests that sta-
tins attenuate neointimal formation and vascular 
remodeling by blocking the activation of the Rho 
family of small G proteins (Rolfe et al., 2005). 
Statins inhibit the activity of HMG-CoA reductase 
which catalyses the conversion of HMG-CoA into 
mevalonate during cholesterol biosynthesis. Me-
valonate can be converted into farnesylpyrophos-
phate (FPP) and geranylgeranylpyrophosphate 
(GGPP), 2 isoprenoid residues that can be anch-
ored onto several intracellular proteins through far-
nesylation or geranylgeranylation (Wong et al., 
2002; Graaf et al., 2004). Simvastatin has been re-
ported to inhibit the relocalization of RhoA to cell 
membranes and the resulting activation of RhoA by 
blocking geranylgeranylation (Laufs et al., 1999). 
However, whether statins can affect the SPC-in-
duced differentiation of MSCs to SMCs has not 
been studied. In the present study, we show for the 
first time that simvastatin inhibits the differentiation 
of hASCs into SMCs by blocking RhoA-Rho kinase- 
dependent activation of autocrine TGF-β/Smad2 
signaling pathway.
Results
Simvastatin inhibits SPC-induced differentiation of 
hASCs to SMCs
To explore whether statin can affect SPC-induced 
differentiation of hASCs to SMCs, we examined 
the effect of simvastatin on the SPC-induced ex-
pression of smooth muscle-specific markers, in-
cluding α-SMA and calponin. As shown in Figure 1, 
SPC treatment increased the expression of α-SMA 
and calponin in hASCs, and simvastatin dose-de-
pendently attenuated SPC-induced expression of 
α-SMA and calponin with a complete inhibition at a 
1 μM concentration, suggesting simvastatin has an 
inhibitory effect on the SPC-induced differentiation 
of hASCs to SMCs. 
    To confirm these results, we determined the ef-
fects of simvastatin on α-SMA expression and ac-
tin filament formation using immunocytochemistry. 
As shown in Figure 1B, treatment of hASCs with 2 
μM SPC for 4 days increased α-SMA expression 
levels, and pretreatment of the cells with simvasta-
tin completely abrogated SPC-induced expression 
of α-SMA in hASCs. Effect of simvastatin on differentiation of MSCs    161
Figure  2. Effects of simvastatin on SPC-induced phosphorylation of 
Smad2 and ERK. (A) hASCs were treated with serum-free medium con-
taining 2 μM SPC or vehicles (0.1% DMSO) in the absence or presence 
of 1 μM simvastatin for 4 days. Phosphorylation levels of Smad2 and ex-
pression levels of Smad2 and GADPH were determined by Western 
blotting. (B) The densities of p-Smad2 were quantified and normalized to 
those of Smad2. Data are expressed as mean ± SD (n =4 ;  * P ＜
0.05). (C) hASCs were pretreated with serum-free medium containing 1 
μM simvastatin or vehicles (0.1% DMSO) for 1 day and then treated with 
2 μM SPC or vehicles for 10 min. Phosphorylation levels of ERK and ex-
pression levels of ERK and GADPH were determined by Western 
blotting. Representative data from three independent experiments are 
shown.
Figure 3. Effect of simvastatin on SPC-induced RhoA activation. (A) 
hASCs were treated with 2 μM SPC for the indicated time periods. (C) 
hASCs were pretreated with serum-free medium containing 1 μM sim-
vastatin or vehicles (0.1% DMSO) for 1 day and then treated with 2 μM 
SPC or vehicles for the indicated time periods. The amounts of RhoA in 
total lysates and membrane fractions were determined by Western 
blotting. (B, D) The densities of RhoA in membrane fractions were quanti-
fied and normalized to those of RhoA in total lysates. Data are expressed 
as mean ± SD (n =4 ;  * P ＜ 0.05). (E) hASCs were pretreated with 1 
μM simvastatin (0.1% DMSO) or vehicles for 1 day, followed by treat-
ment with 2 μM SPC for 5 min. The amounts of RhoA in the whole cell ly-
sates (Total RhoA) or the GTP-bound RhoA precipitated from the lysates 
were revealed by Western blotting. Representative data from three in-
dependent experiments are shown.
Simvastatin inhibits SPC-induced sustained 
phosphorylation of Smad2
We previously reported that SPC treatment elicited 
phosphorylation of Smad2 on day 1 that was sus-
tained until day 4, and that the sustained phos-
phorylation of Smad2 was responsible for the in-
creased expression of α-SMA (Jeon et al., 2006). 
Therefore, we sought to determine the effect of 
simvastatin on SPC-induced Smad2 phosphorylation 
on day 4. As shown in Figures 2A and 2B, treat-
ment of hASCs with SPC for 4 days induced phos-
phorylation of Smad2 and pretreatment of the cells 
with simvastatin markedly attenuated Smad2 
phosphorylation. 
    We  have  shown  that  SPC  elicited  acute  ERK 
phosphorylation in 10 min and ERK phosphor-
ylation played a key role in SPC-induced sustained 
phosphorylation of Smad2 (Jeon et al., 2006). 
Therefore, we examined the effect of simvastatin in 
SPC-induced ERK phosphorylation. As shown in 
Figure 2C, treatment of hASCs with SPC for 10 
min induced phosphorylation of ERK, whereas 
SPC-induced ERK phosphorylation was not attenu-
ated by pretreatment with simvastatin. This sug-
gests that ERK is not a target of simvastatin-in-
duced inhibition of Smad2 phosphorylation and 
α-SMA expression.
Simvastatin inhibits SPC-induced RhoA activation
Increasing body of evidence suggests that 
RhoA-mediated rearrangement of the actin cy-
toskeleton plays a pivotal role in SMC differ-
entiation (Cen et al., 2004). It has been reported 
that activated RhoA translocated from the cytosol 
to the plasma membrane through geranylger-
anylation, and that simvastatin inhibited this trans-
location (Laufs et al., 1999).
    To explore whether SPC can induce RhoA acti-
vation, hASCs were treated with SPC for the in-
dicated periods, and the amounts of mem-
brane-associated RhoA were determined. SPC 
treatment increased the amounts of RhoA asso-
ciated with cell membrane in a time-dependent 
manner, with a maximal increase at 5 min (Figures 
3A and 3B). The SPC-induced translocation of 162    Exp. Mol. Med. Vol. 44(2), 159-166, 2012
Figure 4. Role of RhoA-Rho kinase pathway in the SPC-induced phos-
phorylation of Smad2. (A) hASCs were transfected with the domi-
nant-negative mutant of RhoA (DN-RhoA) or control vector and then 
treated with serum-free medium containing 2 μM SPC or vehicles for 4 
days. (C) hASCs were treated with serum-free medium containing 2 μM 
SPC or vehicles in the absence or presence of 10 μM Y27632 for 4 days. 
Phosphorylation levels of Smad2 and expression levels of Smad2, 
α-SMA, and GAPDH were determined by Western blotting. (B, D) The 
densities of α-SMA were quantified and normalized to those of GAPDH. 
Data are expressed as mean ± SD (n =4 ;  * P ＜ 0.05).
Figure 5. Effect of simvastatin on SPC-induced secretion of TGF-β1. 
hASCs were treated with serum-free medium containing 2 μM SPC or 
vehicles (w/o) in the absence or presence of 10 μM Y27632 or 1 μM 
simvastatin for 2 days. The conditioned medium was subjected to ELISA 
for determination of TGF-β1 protein levels. Data represent mean ± SD 
(n = 4). *indicates P ＜ 0.05.
RhoA was completely abrogated by pretreatment 
of the cells with simvastatin (Figures 3C and D). To 
confirm these results, we determined the amounts 
of GTP-loaded RhoA after treatment with SPC 
and/or simvastatin. As shown in Figure 3E, SPC 
treatment increased GTP-RhoA levels and pre-
treatment with simvastatin abrogated SPC-induced 
increase of GTP-RhoA.
RhoA-Rho kinase is responsible for the SPC-induced 
α-SMA expression and Smad2 phosphorylation
In order to delineate whether RhoA is involved in 
the SPC-induced α-SMA expression and Smad2 
phosphorylation, we examined the effect of a domi-
nant-negative mutant of RhoA (RhoA
N19) on SPC-in-
duced  α-SMA expression and Smad2 phosphor-
ylation. As shown in Figures 4A and 4B, over-
expression of RhoA
N19 attenuated the SPC-in-
duced  α-SMA expression and Smad2 phosphor-
ylation, suggesting that RhoA plays a key role in 
SPC-induced α-SMA expression through a Smad2- 
dependent mechanism.
    To explore whether Rho kinase, a major down-
stream target of RhoA, is involved in SPC-induced 
α-SMA expression and Smad2 phosphorylation in 
hASCs, we examined the effect of Y27632, a Rho 
kinase-specific inhibitor, on α-SMA expression and 
Smad2 phosphorylation induced by SPC. As shown 
in Figures 4C and 4D, SPC-induced α-SMA ex-
pression and Smad2 phosphorylation were abro-
gated by pretreatment of the cells with Y27632, 
suggesting that Rho kinase is involved in SPC-in-
duced  α-SMA expression and Smad2 phosphor-
ylation. Moreover, basal expression levels of α-SMA 
in the absence of SPC treatment were slightly in-
hibited by either DN-RhoA overexpression or pre-
treatment with Y27632, suggesting a potential role 
of RhoA in basal expression of α-SMA as well as in 
the SPC-induced α-SMA expression. 
Simvastatin inhibits SPC-induced secretion of 
TGF-β1 through Rho kinase-dependent mechanism
We previously reported that autocrine secretion of 
TGF-β1 is responsible for SPC-induced Smad2 
phosphorylation and α-SMA expression (Jeon et 
al., 2006). To explore whether the inhibitory effects 
of simvastatin on SPC-induced Smad2 phosphor-
ylation and α-SMA expression are due to the de-
creased secretion of TGF-β1, we measured the ef-
fect of simvastatin on SPC-induced TGF-β1 secretion. 
As shown in Figure 5, SPC stimulated secretion of 
TGF-β1 from hASCs, and pretreatment of the cells 
with simvastatin abrogated SPC-induced secretion 
of TGF-β1. Furthermore, pretreatment of the cells 
with Y27632 inhibited SPC-induced TGF-β1 secretion. 
These results suggest that simvastatin inhibits the 
SPC-induced autocrine TGF-β1/Smad2 signaling 
pathway and α-SMA expression by inhibiting Rho 
kinase-dependent TGF-β1 secretion.Effect of simvastatin on differentiation of MSCs    163
Discussion
The RhoA-Rho kinase signaling pathway plays a 
key role in the SPC-induced differentiation of 
hASCs to SMCs. Inhibition of the RhoA-Rho kinase 
pathway by over-expression of DN-RhoA or pre-treat-
ment with Y27632 completely abrogated SPC-in-
duced α-SMA expression (Jeon et al., 2008). It has 
been documented that the RhoA/Rho kinase-depend-
ent pathway regulates transcription of SMC-specif-
ic genes (Mack et al., 2001; Wamhoff et al., 2004). 
Sphingosine-1-phosphate increased RhoA activity 
and expression level of α-SMA in smooth muscle 
cells, and that inhibition of Rho kinase by Y27632 
attenuated the sphingosine-1-phosphate-stimulated 
α-SMA expression (Lockman et al., 2004). In the 
present study, we demonstrated that simvastatin 
treatment blocked SPC-induced translocation of 
RhoA to membrane fractions and abrogated SPC-in-
duced  α-SMA expression in hASCs. Inactive 
GDP-bound RhoA becomes activated by mem-
brane translocation and subsequent exchange of 
GDP and GTP in the presence of guanine nucleo-
tide exchange factor (Bokoch et al., 1994). Statins 
lead to the deprivation of mevalonate and down-
stream metabolites such as mevalonate, GGPP 
and FPP by blocking HMG-CoA reductase (Nakagami 
et al., 2003). GGPP and FPP are transferred to pro-
teins such as small GTPases by GGPP and FPP, 
respectively (Wong et al., 2002; Graaf et al., 2004). 
Statins has been reported to inhibit membrane lo-
calization and GTP binding activity of RhoA 
(Kusama et al., 2001; Yoshida et al., 2001). Taken 
together, these results support the notion that abla-
tion of RhoA-Rho kinase signaling cascade is re-
sponsible for simvastatin-induced inhibition of 
SPC-induced differentiation of hASCs to SMCs. 
    We have previously showed that SPC-induced 
activation of the autocrine TGF-β1 signaling loop is 
responsible for the sustained phosphorylation of 
Smad2 on day 4 (Jeon et al., 2006). In the present 
study, we demonstrated for the first time that in-
hibition of Rho kinase by treatment with Y27632 or 
simvastatin blocked SPC-induced secretion of 
TGF-β1 and sustained Smad2 phosphorylation. 
Although the molecular mechanisms by which acti-
vation of Rho kinase regulates expression of 
TGF-β1 are largely elusive, a possible role of Rho 
kinase in the regulation of TGF-β1 is supported by 
a report that mechanical stretch of human airway 
SMCs augmented TGF-β1 expression through a 
RhoA-Rho kinase-dependent mechanism (Mohamed 
and Boriek, 2010). Inhibition of Rho kinase by treat-
ment with Y27632 has been reported to abrogate 
renal fibrosis-associated increase of α-SMA ex-
pression and TGF-β1-induced myofibroblastic dif-
ferentiation of gingival fibroblasts (Nagatoya et al., 
2002; Smith et al., 2006). Consistently, inhibition of 
RhoA by C3 exoenzyme or DN-RhoA and pharma-
cological inhibition of Rho kinase by pretreatment 
with Y27632 blocked TGF-β1-induced expression 
of α-SMA in Monc-1 neural crest stem cells (Chen 
et al., 2006). Taken together with these results, the 
present study suggests that Rho kinase is involved 
in the SPC-induced autocrine secretion of TGF-β1 
and subsequent activation of TGF-β receptor and 
Smad2 phosphorylation.
    Differentiation and phenotypic modulation of vas-
cular smooth muscle cells (VSMCs) are implicated 
in the development of vascular diseases including 
atherosclerosis (Rzucidlo et al., 2007). Accumulating 
evidence suggests that MSCs from various tissues 
reside in a perivascular location and can be identi-
fied as pericytes that play a key role in develop-
ment of microvessels (Covas et al., 2008; Feng et 
al., 2010). It has been reported that hASCs also 
originate from perivascular cells (Cai et al., 2011). 
Moreover, several studies suggest that pericytes 
surrounding capillaries and microvessels but also 
adventitial cells located around larger arteries and 
veins natively express MSC markers and multi-
potent differentiation potentials similar to MSCs 
(Chen et al., 2009; Corselli et al., 2010). Therefore, 
these results suggest that MSCs may play a role in 
the vascular development and vascular diseases. 
SPC has been reported to exist in high-density lip-
oprotein (HDL) particles (Tolle et al., 2008). Increasing 
body of evidence demonstrate that HDL exerts an-
ti-atherogenic and anti-inflammatory effects (Nofer 
et al., 2004; Scanu and Edelstein, 2008). HDL in-
duced expression of TGF-β2, an anti-inflammatory 
cytokine, in human umbilical vein endothelial cells 
and SPC mimicked the effect of HDL (Norata et al., 
2005). These results suggest that SPC included in 
HDL may promote differentiation of tissue-resident 
MSCs or pericytes to SMCs, and that statins can 
interfere the differentiation of MSCs to SMCs. 
Similar to the results of the present study, it has 
been reported that TGF-β1-induced  α-SMA ex-
pression in human tenon fibroblasts was attenu-
ated by treatment with lovastatin, a member of the 
statin family (Meyer-Ter-Vehn et al., 2008). However, 
lovastatin treatment has been shown to stimulate 
α-SMA expression in VSMCs and prevent pheno-
typic dedifferentiation of VSMCs (Wada et al., 
2008; Wagner et al., 2010). These results raise a 
possibility that statins differentially affect ex-
pression of SMC markers in different cell types. To 
clarify functional role of statins on MSC differ-
entiation, it is necessary to determine further 
whether statins can affect differentiation of MSCs 
to SMCs using in vivo vascular disease animal 164    Exp. Mol. Med. Vol. 44(2), 159-166, 2012
models such as atherosclerosis and vascular injury 
that are associated with phenotypic modulation of 
SMCs.
Methods
Materials
Trypsin, α-minimum essential medium, fetal bovine serum, 
and Lipofectamine 2000 reagent were purchased from 
Invitrogen (Carlsbad, CA). Y27632 and simvastatin were 
purchased from Calbiochem (La Jolla, CA). D-erythro-SPC 
was purchased from Matreya (Pleasant Gap, PA). 
Anti-α-SMA antibody was purchased from Sigma-Aldrich 
(St. Louis, MO). Anti-phospho-Smad2 (Ser465/467) and 
anti-Smad2 antibodies were obtained from Cell Signaling 
Technology (Beverly, MA). Anti-RhoA antibody was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
antibody was purchased from Millipore (Temecula, CA). 
Peroxidase-labeled secondary antibodies were obtained 
from Amersham Biosciences (Franklin Lakes, NJ). 
Cell culture
Subcutaneous adipose tissue was obtained from elective 
surgeries with the patient’s consent as approved by the 
Institution Review Board of Pusan National University 
Hospital. To isolate hASCs, adipose tissues were washed 
at least three times with sterile PBS and treated with an 
equal volume of collagenase type I suspension [1 g/liter of 
Hank’s balanced salt solution (HBSS) buffer with 1% bo-
vine serum albumin] for 60 min at 37
oC with intermittent 
shaking. The floating adipocytes were separated from the 
stromal-vascular fraction by centrifugation at 300 × g for 5 
min. The cell pellet was resuspended in α-minimum essen-
tial medium supplemented with 10% fetal bovine serum, 
100 U/ml penicillin, and 100 μg/ml streptomycin, and cells 
were plated in tissue culture dishes at 3500 cells/cm
2. 
Primary hASCs were cultured for 4-5 days until they 
reached confluence and were defined as passage “0.” The 
passage number of hASCs used in these experiments was 
3-10. Adipose tissues were collected from six different pa-
tients, and six different hASC clones exhibited similar dif-
ferentiation potentials toward osteogenic and adipogenic 
lineages as well as SMCs. Multipotent differentiation and 
proliferation capacities of hASCs remained consistent up 
until 10th passage. These six hASC clones exhibited 
SPC-induced α-SMA expression which could be inhibited 
by simvastatin treatment. They were positive for CD29, 
CD44, CD73, CD90, and CD105, whereas CD31 and 
CD45 were not expressed in hASCs (Supplemental Data 
Figure S1).
Western blotting
Confluent, serum-starved hASCs were treated with the ap-
propriate conditions, washed with ice-cold PBS, and then 
lysed in lysis buffer (20 mM Tris-HCl, 1 mM EGTA, 1 mM 
EDTA, 10 mM NaCl, 0.1 mM phenylmethylsulfonyl fluoride, 
1 mM Na3VO4, 30 mM sodium pyrophosphate, 25 mM 
β-glycerol phosphate, and 1% Triton X-100, pH 7.4). 
Lysates were resolved by SDS-PAGE, transferred onto a 
nitrocellulose membrane, and then stained with 0.1% 
Ponceau S solution (Sigma-Aldrich). After blocking with 
5% nonfat milk, the membranes were immunoblotted with 
various antibodies, and the bound antibodies were vi-
sualized with horseradish peroxidase-conjugated secon-
dary antibodies using the enhanced chemiluminescence 
Western blotting system (ECL, Amersham Biosciences). 
Images were obtained using a LAS3000 image capture 
system (FUJIFILM, Japan). The immunoblots were quanti-
fied by measuring the intensity of the protein bands with 
LAS3000 software. Immunoblot images were obtained at 
different exposure times, and images whose band in-
tensities were within the linear range between the intensity 
increase and exposure time were selected for quantifica-
tion of images.
Measurement of membrane translocation of RhoA 
To determine the amounts of membrane-associated RhoA, 
membrane fractions were isolated as previously described 
(Negre-Aminou et al., 2001). Cells were made quiescent 
and stimulated as described in the figure legends. They 
were then washed in ice-cold PBS, lysed by incubation in 
hypotonic buffer (5 mM Tris-HCl, 5 mM NaCl, 1 mM CaCl2, 
2 mM EGTA, 1 mM MgCl2, and 2 mM dithiothreitol, pH 7.0) 
containing a mixture of protease inhibitors. Membrane frac-
tions were separated from cytosolic fractions by cen-
trifugation (100,000 × g, 1 h at 4
oC) of the lysates. 
Membrane fractions were prepared by resuspending the 
pellets in the hypotonic buffer. The lysates and membrane 
fractions were diluted in SDS-PAGE buffer and the protein 
levels of RhoA were determined by Western blotting.
RhoA activation assay
A commercial pull-down assay (Rho activation assay kit, 
Upstate) was used to measure the effect of SPC on RhoA 
activity in hASCs. The cells were treated washed twice 
with  α-MEM and incubated for 24 h in fresh modified 
α-MEM without serum, SPC was added, and the cell sus-
pension was centrifuged at the indicated time after SPC 
addition. After lysis of the cell pellet (lysis buffer, Upstate) 
and the activated RhoA was precipitated using a fusion 
protein consisting of GST and the Rho binding domain of 
Rhotekin, according to the manufacturer’s protocol. Protein 
concentrations were equalized between treatment groups 
prior to pull-down assay. 
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde in PBS for 15 
min. For immunostaining, specimens were incubated with 
anti-α-SMA antibody for 2 h and Alexa Fluor 488-con-
jugated anti-mouse secondary antibody (Invitrogen) for 1 h. 
The specimens were finally washed and mounted in 
Vectashield medium (Vector Laboratories) with 4',6-dia-
midino-2-phenylindole (DAPI) for visualization of nuclei. 
Fluorescence images were collected using a Leica TCL-SP2 
confocal microscope system (Leica Microsystems Heidelberg 
GmbH, Heidelberg, Germany). Effect of simvastatin on differentiation of MSCs    165
ELISA
ELISA was carried out according to the manufacturer's 
instructions. In brief, cells were seeded onto 24-well culture 
plates at a density of 1 × 10
4 cells/well and cultured in 
growth medium for 48 h to confluence. After treatment of 
the confluent cells under appropriate conditions, con-
ditioned media were collected and centrifuged at 15000 ×
g for 30 min to remove particulates. A commercially avail-
able sandwich ELISA kit (R&D Systems Inc., Minneapolis, 
MN) was used to evaluate the secretion of TGF-β1 in the 
conditioned medium. The absorbance (450 nm) for each 
sample was analyzed by an ELISA reader and was inter-
polated with a standard curve.
Supplemental data
Supplemental data include a figure and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-44-2-11.pdf.
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